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Background: Primary ovarian insufficiency (POI) is heterogeneous disease defined by amenorrhea or premature
depletion of ovarian follicles before the age of 40 years. The etiology of POI is still unclear. The purpose of this
study is to evaluate whether women with POI have an elevated serum levels of autoimmunologic parameters.
Methods: The serum from peripheral blood samples which come from 96 POI patients and 100 age-matched
health women were analyzed for a series of autoimmune antibodies using protein microarray. The antibodies to
double-stranded DNA (ds-DNA), histone (HIS), nuclear ribonucleoprotein (RNP), Sjogren’s syndrome A (SSA/Ro),
Sjogren’s syndrome B (SSB/La) and Smith antigen, Jo-1, scleroderma-associated antigen (Scl-70) and centromere
(CEN), zona pellucid (ZP), adrenocortical antibodies (ACA),Rheumatoid factor (RF), glomerular basement membrane
(GBM), proliferating cell nuclear antigen (PCNA), myeloperoxidase (MPO), proteinase 3 (PR3), thyroid microsomal
antibody and antinuclear antibody (ANA)were analyzed.
Results: Among the 96 women with POI and 100 age-matched health controls, women with POI had significantly
elevated circulation levels of Jo-1 and PR3 (p = 0.010 and p = 0.001) whereas circulation levels of ANAs, dsDNA, histone,
RNP, Sm, Scl-70, SSA, SSB, CEN, ZP, ACA, RF, GBM, PCNA, MPO and TM antibodies were similar between the two groups.
Conclusions: This study shows that the autoimmune antibodies JO-1 and PR3 were significantly higher in POI women
group which suggested that these antibodies may have played special role in POI, but the evaluation of the exact
pathways of them remains to be determined.
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In the normal course, a woman enters menopause at
a mean age of 51 years (41-60 years). However, early
menopause occurs approximately 1% of women before
40 years of age, approximately 0.1% of women under 30
and 0.01% of women younger than 20. This condition is
termed as premature ovarian failure (POF), also referred
to as primary ovarian insufficiency (POI), characterized
by amenorrhea, sex steroid deficiency and elevated levels
of gonadortropins. The etiologies include genetic causes,
enzymatic and gonadotropin defects, ovarian insults,
and autoimmunity. Approximately 20-30% of the cases
with POI have associated autoimmune disorders [1]. A* Correspondence: jie.qiao@263.net
1Department of Obstetrics and Gynecology, Peking University, Third Hospital,
No. 49 HuaYuan North Road, HaiDian District, Beijing 100191, China
2Key Laboratory of Assisted Reproduction, Ministry of Education, Beijing,
China
Full list of author information is available at the end of the article
© 2014 Zhen et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orvariety of auto-immune conditions such as endocrinopa-
thy, thyroid diseases, addision’s disease, rheumatoid
arthritis and polyglandular syndrome have been found in
POI women.
A number of autoimmunologic diseases exhibit circu-
lating characteristics. Antibodies to thyroid microsomal
[2] and myeloperoxidase (MPO) are associated with
graves’ disease and thyroiditis [3], antinuclear antibodies
(ANA) and rheumatoid factor(RF) represent a serology
hallmark in the diagnosis of systemic autoimmune rheum-
atic disease (SARD) such as systemic lupus erythematosus
[4]. Zona pellucida antibodies are associated with POI,
antibodies to double-stranded DNA (ds-DNA), histone,
nuclear ribonucleoprotein (RNP) and Smith antigen [5]
are associated with SLE, whereas antibodies to Sjogren’s
syndrome A (SSA/Ro) and Sjogren’s syndrome B(SSB/La)
can occur in both SLE and Sjogren’s syndrome (SS).
Antibodies to MPO and proteinase 3 (PR3) have beentd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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body (ACNA)-associated disease which is the target of
anti-neutrophil cytoplasm antibodies in granulomatosis
with polyangiitis [6]. Antibodies to Jo-1 was observed in
polymyositis and dermatomyositis, whereas antibodies to
scleroderma-associated antigen (Scl-70) and centromere
can occur in patients with progressive systemic sclerosis
(PSS) [7]. Anti-glomerular basement membrane antibody
is associated with glomerulonephritis [8]. Anti-RNP anti-
bodies are linked with mixed connective tissue disease
(MCTD) and SLE, anti-PCNA antibodies have been de-
scribed in a variety of SARD.
The aim of the present study was to investigate a panel
of serologic autoimmunologic parameters in POI women
and contributed further data on autoimmunologic pro-
cesses and to elucidate potential mechanisms for their
interrelation in POI.
Methods
Selection criteria of patients and controls
A total of 96 patients and 100 controls were included in
this study. A written consent was obtained from all pa-
tients and controls for their participation in the study.
All of the procedures were carried out in compliance
with the Declaration of Helsinki. This study was ap-
proved by the Peking University Third Hospital ethical
committee (IRB00006761-2011022, about the details of
the ethics statement please see the Additional file 1).
The inclusion criteria were (1) age <40 years, (2) amen-
orrhea for > 6 months, (3) FSH > 40IU/L (two times apart
more than one month), (4) chromosome Karyotype is
46 XX. Control subjects were enrolled by the criteria (1)
age-matched with the POI group, (2) menstrual rules,
(3) hormone level was normal. None of them had a per-
sonal or family history of hereditary disease and pelvic sur-
gery and no radiation and chemotherapy histories (such as
previous pelvic irradiation, operative castration, and previ-
ous cytotoxic chemotherapy were excluded).
Blood was collected from the recruited individuals,
serum separated, stored at −20°C till further use.
Detection of antibodies
A protein microarray-based detection kit (CapitalBio,
Beijing) was used, 18 antigens related with the serum
autoimmune antibodies were immobilized on the micro-
array. The principle is to carry out a relative quantitative
detection on the related antibodies using an indirect im-
munofluorescence assay on the chip. First of all, on-chip
fixed antigens were reacted with lgG antibodies in the
serum sample to form antigen - antibody complexes. The
quantity of the antigen - antibody complex depends on
the amount of specific lgG antibodies in serum. Then add
excessive amount of Cy3 fluorescent labeled anti-human
lgG antibody (secondary antibody) to the microarraywhich will interact with the complex to form the antigen-
antibody-fluorescent-antibody complex, and the amount
of the antigen-antibody-fluorescent-antibody complex on
the array depends on the amount of antigen-antibody
complex. The microarray was scanned by LuxScan 10K-B
microarray scanner to detect the fluorescence signals on
the array to form an image. Finally, the data was analyzed
by the interpreted software on the machine and the serum
concentrations of specific antibody were calculated.
Data was analyzed using a cutoff value to determine
an antibody positive result. The cutoff value was equi-
valent to the mean value for the serum assay controls
(n = 100) plus 2SD (95% CI) or 3SD (99% CI).
Statistical analysis
Quantitave data were expressed as mean ± SD, T-test
and chi-square or Fisher exact test were used to com-
pare hormone serum levels, BMI, ovarian volume and
antibodies. All tests applied two-tailed, and the signifi-
cance level was defined as p value < 0.05. Statistical ana-
lysis was performed with the SPSS 11.5 package.
Results
Among the 96 patients, 9 patients had histories of Mumps,
5 patients had histories of tuberculosis, 4 patients had
histories of thyroid disorders and 2 patients had histor-
ies of diabetes mellitus. 10 of the patients presented
with primary amenorrhea, 86 patients presented with
secondary amenorrhea. The characters of POI and
healthy women were seen in Table 1.
When a cutoff value (95% CI) was used, the number of
positive PR3 and Jo-1 antibody were significantly higher in
women with POI (15/96 & 3/100, p = 0.002 and 12/96 &
3/100, p = 0.012) whereas the circulation levels of ANAs,
dsDNA, ssDNA, histone, RNP, Sm, Scl-70, CEN, ZP, AC,
RF, GBM, PCNA, MPO and TM antibodies were similar
between the two groups. A higher cutoff value (99% CI)
reduced the proportion of positive antibodies. Using the
higher cutoff value, PR3 and Jo-1 antibodies from the
women with POI remained significantly different from
antibodies from Control group (Table 2).
The level of positivity of anti-PR3 and anti-JO-1 ob-
served in POI patients have been presented in figures
(see the Additional files 2 and 3).
Discussion
Variety of possible causes of POI reflects the heterogen-
eity of POI. None of the causes seems to predominate.
However, their true incidence in the majority of the cases
of POI remains unclear, so the scientists working in this
area should be focus on the etiology of POI [9]. Auto-
immunity appears to play a role in some cases of POI.
The study shows that POI women group have significant
higher levels of Jo-1 and PR3 antibodies (p = 0.010 and
Table 1 Characteristics of the POI and health control women
Parameter POI (Range) N = 96 Health (Range) N = 100
Age (year) 27.6 ± 4.51 (21-38) 27.5 ± 4.57 (21-39)
Menarche (age) 13.5 ± 1.71 (12-18) 13.4 ± 1.15 (12-15)
Amenorrhea (year) 6.33 ± 4.71 (2-18) 0
BMI (kg/m2) 20.5 ± 2.12 (16-27) 20.33 ± 1.56 (18-25)
FSH (IU/L) 80.25 ± 33.6 (44.7-140.2)* 7.6 ± 1.74 (5.35-9.7)
LH (IU/L) 38.65 ± 14.8 (20.4-89.7)* 4.29 ± 1.89 (2.89-9.56)
E2 (pmol/L) 80.4 ± 13.3 (73.4-109)* 136 ± 53.9 (96.9-240)
T (nmol/L) 0.781 ± 0.29 (0.69-1.28)** 1.32 ± 0.379 (1.21-2.19)
A (nmol/L) 5.46 ± 1.9 (2.5-6.7) 6.02 ± 1.97 (4.3-8.9)
Ovarian volume (ml)# 1.512 ± 2.01 (0.489-7.53)* 13.1 ± 1.61 (9.63-19.8)
*p = 0.000, **p = 0.002, #ovarian volume was the average of two side of ovary volume, ovarian volume were calculated using the formula for a prolate ellipsoid:
Longitudinal diameter × anterioposterior diameter × transverse diameter × 0.5233.
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histone, RNP, Sm, Scl-70, CEN, ZP, AC, RF, GBM, PCNA,
MPO and TM antibodies were similar between the two
groups.
Autoimmune mechanisms are involved in the patho-
genesis of up to 30% of cases in idiopathic POI [10]. It
has been estimated that, in adult patients with POI, 18-
30% also have an autoimmune disease and up to 50%Table 2 Summarize of the laboratory findings in women






SSA (%) 4.2 (4/96) 2 (2/100) 0.322
Sm (%) 0 0 –
SCL70 (%) 10.4 (10/96) 6 (6/100) 0.304
JO1 (%) 10.4 (10/96) 2 (2/100) 0.010
SSB (%) 26 (25/96) 15 (15/100) 0.076
RNP (%) 7.3 (7/96) 4 (4/100) 0.366
CENPB (%) 2.1 (2/96) 2 (2/100) 1.000
ANA (%) 19.8 (19/96) 14 (14/100) 0.341
ZP 11.5 (11/96) 8 (8/100) 0.474
ACA 1 (1/96) 1 (1/100) 1.000
MPO 2.1 (2/96) 1 (1/100) 0.615
PR3 14.6 (14/96) 2 (2/100) 0.001
TM 8.3 (8/96) 6 (6/100) 0.587
RIBP 10.4 (10/96) 8 (8/100) 0.626
RNPA 8.3 (8/96) 5 (5/100) 0.400
PCNA 3.1 (3/96) 3 (3/100) 1.000
dsDNA 2.1 (2/96) 0 0.239
HISTONES 1 (1/96) 0 0.490
GBM 4.2 (4/96) 3 (3/100) 0.717
RF 0 0 –
#The cutoff value was equivalent to the mean value for the serum assay
controls (n = 100) plus 3SD (99% CI).have other evidence of autoimmunity [11]. The diagno-
sis of autoimmunity diseases relies on clinical, biological
and histologic parameters. But in our study, all patients
and healthy control women had no clinical symptom
of autoimmunity disease. Detection of specific autoan-
tibodies remains the most practical clinical research
marker of any of autoimmune disease, so we selected a
panel of well-established markers which are used in the
diagnosis of autoimmunity diseases to investigate sero-
logic autoimmunologic parameters in POI women. To
our knowledge, no such data have been published in
women with POI.
Human ovary is commonly the target of an autoimmune
attack in cases of organ or non-organ specific auto-
immune disorders leading to the ovarian dysfunction.
Colafrancesco et al. described three clinical cases who
developed premature ovarian failure following adminis-
tration of the HPV vaccine [12]. Autoimmune etiology
includes the presence of lymphocytic oophoritis, auto-
antibodies to ovarian antigens and associated auto-
immune disorder. Anti-ovarian antibodies have been
demonstrated in patients with SLE and primary Sogren’s
syndrome and polyglandular syndrome [13]. Auto-
immunity is an important mechanism for accelerated
destruction of ovarian follicles.
Development of ovarian auto-antibodies is a causative
factor in most POI cases. Although controversial, the
presence of circulating antiovarian antibodies (AOA)
may be considered a marker of autoimmune premature
ovarian failure. Vallotton and Forbes were the first to
describe the presence of antibodies from POI serum.
Prevalence of antibodies in POI patients varied among
investigators from 24%-73.3%. Different antibody test
format, antigen preparation and criteria for different
studies and several antigenic targets lead to different re-
sults [14-17]. Wheatcroft et al. reported an incidence
ranging from 24-60%, depending on the source of
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in the detection of ovarian antibodies in serum is the higher
rate of false positives. ZP is an extracellular matrix that
surrounds the mammalian oocyte and plays an import-
ant role in normal folliculogenesis and fertilization, so
ZP could be an important ovarian antigen [18,19]. Pires
et al. indicated that several proteins from other cellular
targets such as oocytes, corpus luteum, theca and gran-
ulose cells are also involved in ovarian autoimmunity
[20]. In our study, with its strong immunogenicity and
its possible relation with premature ovarian failure, we
use the human ZP as antigen, but no difference was ob-
served in the serum level of AOA between POI patients
and control (11.5% & 8%).
Our data show that circulations level of PR3 and Jo-1
antibody are elevated in women with POI compared
with healthy women. PR3 is the target of anti-neutrophil
cytoplasm Abs (ANCA) in granulomatosis with polyan-
giitis, a form of systemic vasculitis [6,21]. In our study,
among 96 POI patients, 14 patients have anti-PR3 higher
levels, which 3 patients had histories of mumps, and the
others have no any medical history. Anti-Jo-1 antibody,
one of the aminoacyl tRNA synthetases antibodies, is
associated with a more abrupt onset of fever, cracked
hands, Raynaud’s phenomenon, interstitial lung disease,
arthritis and PM/DM, which was reported in 20-30% of
patients with PM/DM. Antibody to Jo-1 is a kind of
anti-nuclear antibody. Anti-Jo-1 antibody levels corre-
lated modestly with muscle and joint disease and more
striking associations emerged in a smaller longitudinal
subset of patients that link anti-jo-1 antibody levels to
muscle, joint, lung, and global disease activity [22-24].
there are 10 patients who had positive anti-Jo-1 anti-
body, 2 patients had histories of tuberculosis and 2 pa-
tients had histories of diabetes mellitus. The high level
of PR3 and Jo-1 antibody suggest that a role for autoim-
munologic process might be present in pathogenesis of
POI. But the evaluation of the exact pathways of these
antibodies remains to be determined.
Autoimmune diseases, such as autoimmune thyroiditis,
diabetes mellitus type1, poparathyroidism, SLE, rheuma-
toid arthritis and Addison’s disease, frequently coexist with
POI. 10-40% of women with POI have clinical autoim-
mune disease, the most common of these is hypothyroid-
ism with an incidence of 27%, followed by diabetes
mellitus (2.5%) and Addison’s disease (2.5%) [10,25]. In
our study, 4 and 2 patients had histories of thyroid
disorder and diabetes mellitus respectively whereas there
was no thyroid disorder and diabetes mellitus in healthy-
control women. Absence of clinical evidence of other
endocrine autoimmune disease, POI patients often ex-
hibit organ-specific auto-antibodies, but there were no
significant in antibodies to dsDNA, histone, RNP, Sm,
Scl-70, CEN, AC, GBM, PCNA, MPO, TM between thetwo groups (P > 0.05). Joe Feuerstein reported reversal
of premature ovarian failure in a patient with Sjogren
syndrome, laboratory tests showed a positive ANA, and
a positive SS-A Sjogren antibody, positive anti-CCP and
positive anti-Smith [26].
There are no convincing data at this time that pa-
tients with systemic autoimmune disorders such as
SLE or rheumatoid arthritis (RA) have higher rates of
POI than that of general population. But non-organ
specific autoantibody has been reported in patients in
POI, including antinuclear antibodies and rheumatoid
factor [27]. ANA positivity of 42-77% has been re-
ported among chromosomally normal women with
POI, POI is not a well-described complication of sys-
temic lupus erythematosis [4] and a positive rheuma-
toid factor. Interestingly, development of new onset
SLE has been associated with slightly earlier age of nat-
ural menopause and early age at menopause may be a
risk factor for development of rheumatoid arthritis. In
our study, there is no significant in ANAs, RF between
POI and healthy women groups.
Screening serologic tests, however, are not necessarily
recommended because of high false-positive rates. Sero-
logic tests are most useful in confirming or ruling out
the diagnosis; for example, SLE is rarely present when
ANAs are absent; the absence of RF will not rule out
RA, but its presence confirms it. Polymyalgia rheuma-
tica and RA, with an incidence of 1 in 2000 to 3000, are
the most common autoimmune disorders. Other auto-
immune diseases such as SLE, vasculitis, polymyositis,
and dermatomyositis are seen infrequently in general
practice. Menopause may affect disease prognosis and
treatment.
Mumps oophoritis has been considered to be a cause
of POF [28-30], in our study there are 9 patients who
had mumps histories. 3 patients have positive PR3 and
the others have no any positive antibody.
Our study shows that serum levels of Jo-1 and PR3
antibodies are elevated in women with POI compare
with health controls. These results suggest that a role for
autoimmunologic process might be present in pathogen-
esis of POI. Whether or not women with POI are at an
increased risk for developing autoimmune diseases is
unknown and should be investigated in future trials. The
weaknesses of this study are the absence of a direct clin-
ical implication and the necessity elucidating the pos-
sible pathways involved.
Conclusions
This study shows that JO-1 and PR3 antibodies were sig-
nificantly higher in POI women group and may be related
with POI, which might help to determine the real preva-
lence of autoimmune POI. The interplay of autoimmunity
with the reproductive endocrine system is complex and
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serologic autoimmunologic parameters in women with
POI here. The evaluation of the exact pathways of these
antibodies to POI remains to be determined.
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